CERC CERECOR INC

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors
EN
12/10/2020

Underlying

CERCCERECOR INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERECOR INC

 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Announces Inducement Grants to New Employees Under ...

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 82,000 shares of common stock (the “Options”) as inducem...

February 18, 2026 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 10:00 am ET Live webcasts ...

February 4, 2026 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Announces Inducement Grants to New Employees Under ...

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as indu...

November 17, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Re...

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechno...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CERC CERECOR INC

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation ConferenceFireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare ConferenceFireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1st Immunology & Inflamm...

November 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch